(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of 10.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.63%.
Enanta Pharmaceuticals's revenue in 2025 is $67,635,000.On average, 5 Wall Street analysts forecast ENTA's revenue for 2025 to be $1,561,004,499, with the lowest ENTA revenue forecast at $1,208,076,582, and the highest ENTA revenue forecast at $2,313,784,569. On average, 5 Wall Street analysts forecast ENTA's revenue for 2026 to be $1,449,268,012, with the lowest ENTA revenue forecast at $679,066,205, and the highest ENTA revenue forecast at $2,313,784,569.
In 2027, ENTA is forecast to generate $2,070,812,816 in revenue, with the lowest revenue forecast at $644,095,567 and the highest revenue forecast at $4,845,022,924.